Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

118results about How to "Ability to inhibit migration" patented technology

Preparation method of heat stability-enhanced porous silver-magnesium-aluminum alloy film

The invention discloses a preparation method of a heat stability-enhanced porous silver-magnesium-aluminum alloy film, and relates to the technical field of photoelectric materials. The preparation method comprises the following steps: firstly preparing a silver-magnesium-aluminum alloy film through a thin film deposition technology, wherein the silver-magnesium-aluminum alloy film is prepared from the following chemical components in percentage by mass: 50 to 60 percent of a magnesium element, 3 to 10 percent of an aluminum element and 30 to 47 percent of a silver element; and then corroding active metals through dealloying reaction liquid, thus forming a nano porous structure which takes silver as a framework and is doped with a little of aluminum and magnesium. After being subjected to high temperature treatment, the porous silver-magnesium-aluminum alloy film prepared through the preparation method still can keep the porous structure, so that a relatively wide absorption spectrum and a relatively good absorption effect can be kept. The preparation process is simple, the repetitiveness is high, and the cost is low; the shortcoming in the heat stability of a porous silver-based film in the prior art can be overcome; and actual popularization and application of the porous silver-based film are facilitated.
Owner:UNIV OF ELECTRONIC SCI & TECH OF CHINA

Angstrom silver oral liquid and preparation method and application in gastric cancer treatment thereof

The invention discloses angstrom silver oral liquid and a preparation method and application in gastric cancer treatment thereof. The angstrom silver oral liquid is prepared from angstrom silver element powder, medicinal sugar and high-purity distilled water. The preparation method comprises the steps that the angstrom silver element powder is added to the high-purity distilled water to obtain anangstrom silver solution; dispersing treatment is conducted on the angstrom silver solution; the medicinal sugar is added to the dispersed angstrom silver solution, and dispersing treatment is conducted again; the dispersed angstrom silver solution is heated and sterilized, and the angstrom silver oral liquid is obtained after natural cooling is conducted. Angstrom silver injection has significantgastric cancer cell proliferation and migration inhibition capability. The appearance and weight of primary organs are not significantly changed after oral consecutive application of angstrom silveris conducted for 15 days, and H&E dyeing and immunohistochemical analysis prove that the expression amount of tissues structures and activated Caspase-3 of the primary organs after angstrom silver application is conducted is not significantly changed.
Owner:SHENZHEN AMCAN MEDICAL BIOTECH LTD

Long chain noncoding RNA-HOTAIR molecular marker for colorectal cancer and application of long chain noncoding RNA-HOTAIR molecular marker

The invention discloses a long chain noncoding RNA marker for auxiliary diagnosis of colorectal cancer (CRC). Long chain noncoding RNA is HOTAIR; auxiliary diagnosis or prediction of patient conditiondevelopment of the CRC can be realized by detecting expression quantity of the long chain noncoding RNA; differentiation, infiltration depth, proliferation and metastasis conditions of the CRC can bepredicted by monitoring expression conditions of p21 and a value of judging prognosis is realized. Expression level of LncRNA HOTAIR gene can be detected by RT-qPCR, real-time quantitative PCR, immunodetection, in-situ hybridization, chip or a high-throughput sequencing platform; meanwhile, the invention also discloses silencing HOTAIR which can obviously inhibit the proliferation, migration andinvasion abilities of CRC cells, reduce the expression of PCNA, Ki67, cyclin E and CDK2 and medicate expression increase of p21. The invention provides a molecular marker for the CRC and provides theoretical basis for mechanism research and clinical individualized therapy of the CRC; a brand-new treatment strategy can be provided for clinically treating the CRC by monitoring the expression of theLncRNA HOTAIR in the CRC.
Owner:汕头大学医学院附属肿瘤医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products